Drug treatment developments in schizophrenia and bipolar mania: Latest evidence and clinical usefulness

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 6, 2012, Pages 287-300

  Johnsen, Erik ^a   Kroken, Rune A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Mania; Psychotropic drugs; Review; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CLOZAPINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HALOPERIDOL DECANOATE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AKATHISIA; BIPOLAR MANIA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; META ANALYSIS (TOPIC); METABOLIC DISORDER; MORTALITY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84875511872     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312462275     Document Type: Review

References (96)

1. Abi-Dargham A. Laruelle M. (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry, 20, 15–27.
2. Altamura A. Lietti L. Dobrea C. Benatti B. Arici C. Dell'Osso B. (2011) Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother 11: 85–99.
3. Álvarez-Jiménez M. Parker A. Hetrick S. McGorry P. Gleeson J. (2011) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 37: 619–630.
4. Arranz M. de Leon J. (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12: 707–747.
5. Arranz M. Rivera M. Munro J. (2011) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25: 933–969.
6. Asenjo Lobos C. Komossa K. Rummel-Kluge C. Hunger H. Schmid F. Schwarz S. et al. (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11: CD006633.
7. Barnes T. and Schizophrenia Consensus Group of British Association for Psychopharmacology (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25: 567–620.
8. Beynon S. Soares-Weiser K. Woolacott N. Duffy S. Geddes J.R. (2009) Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 23: 574–591.
9. Biedermann F. Fleischhacker W. (2011) Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 16: 271–282.
10. Bromet E. Fennig S. (1999) Epidemiology and natural history of schizophrenia. Biol Psychiatry 46: 871–881.
11. Buchanan R. Kreyenbuhl J. Kelly D. Noel J. Boggs D. Fischer B. et al. (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71–93.
12. Cipriani A. Barbui C. Salanti G. Rendell J. Brown R. Stockton S. et al. (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378: 1306–1315.
13. Citrome L. (2012) A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 13: 1545–1573.
14. Cookson J. Hodgson R. Wildgust H. (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 26(5 Suppl.): 42–51.
15. Correll C. Leucht S. Kane J. (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414–425.
16. Correll C. Schenk E. (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21: 151–156.
17. Crossley N. Constante M. McGuire P. Power P. (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196: 434–439.
18. de Hert M. Correll C. Bobes J. Cetkovich-Bakmas M. Cohen D. Asai I. et al. (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52–77.
19. Delay J. Deniker P. Harl J. (1952) [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann Med Psychol (Paris) 110: 112–117.
20. Delgado-Rodriguez M. (2006) Systematic reviews of meta-analyses: applications and limitations. J Epidemiol Community Health 60: 90–92.
21. Depp C. Lebowitz B. (2007) Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry 19: 531–539.
22. Derry S. Moore R. (2007) Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 7: 40.
23. Gaebel W. Riesbeck M. Wobrock T. (2011) Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry 23: 379–387.
24. Gaebel W. Weinmann S. Sartorius N. Rutz W. McIntyre J. (2005) Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 187: 248–255.
25. Galbally M. Roberts M. Buist A. and Perinatal Psychotropic Review G. (2010) Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 44: 967–977.
26. Gentile S. (2010) Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36: 518–544.
27. Gentile S. (2011) Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 24: 34–40.
28. Gentile S. (2012) Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf 11: 425–437.
29. Glick I. Correll C. Altamura A. Marder S. Csernansky J. Weiden P. et al. (2011) Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 72: 1616–1627.
30. Haddad P. Das A. Keyhani S. Chaudhry I. (2012) Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 26(5 Suppl.): 15–26.
31. Haddad P. Tiihonen J. Haukka J. Taylor M. Patel M. Korhonen P. (2011) The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophr Res 131: 260–261.
32. Hatta K. Sato K. Hamakawa H. Takebayashi H. Kimura N. Ochi S. et al. (2009) Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res 113: 49–55.
33. Heres S. Davis J. Maino K. Jetzinger E. Kissling W. Leucht S. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185–194.
34. Hippius H. (1989) The history of clozapine. Psychopharmacology (Berl) 99(Suppl.): S3–S5.
35. Howes O. Kapur S. (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 35: 549–562.
36. Johnsen E. Jorgensen H. (2008) Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8: 31.
37. Johnsen E. Kroken R. Wentzel-Larsen T. Jorgensen H. (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10: 26.
38. Jones P. Barnes T. Davies L. Dunn G. Lloyd H. Hayhurst K. et al. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087.
39. Kahn R. Fleischhacker W. Boter H. Davidson M. Vergouwe Y. Keet I. et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–1097.
40. Kane J. Correll C. (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71: 1115–1124.
41. Kessing L. Hellmund G. Andersen P. (2012) An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 26: 644–652.
42. Kessing L. Hellmund G. Geddes J. Goodwin G. Andersen P. (2011) Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 199: 57–63.
43. Kessler R. Petukhova M. Sampson N. Zaslavsky A. Wittchen H. (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21: 169–184.
44. Kishimoto T. Agarwal V. Kishi T. Leucht S. Kane J. Correll C. (2011) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 29 November (Epub ahead of print).
45. Klemp M. Tvete I. Skomedal T. Gaasemyr J. Natvig B. Aursnes I. (2011) A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol 31: 698–704.
46. Kroken R. Johnsen E. (2012) Is rational antipsychotic polytherapy feasible? A selective review. Curr Psychiatry Rep 14: 244–251.
47. Kroken R. Mellesdal L. Wentzel-Larsen T. Jorgensen H. Johnsen E. (2011) Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia. Eur Psychiatry 15 June (Epub ahead of print).
48. Kuipers E. (2009) Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). National Clinical Practice Guideline 82. London: National Institute for Health and Clinical Excellence.
49. Kupka R. Altshuler L. Nolen W. Suppes T. Luckenbaugh D. Leverich G. et al. (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9: 531–535.
50. Lenox R. Watson D. (1994) Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness. Clin Chem 40: 309–314.
51. Leucht C. Heres S. Kane J. Kissling W. Davis J. Leucht S. (2011 a) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127: 83–92.
52. Leucht S. Arbter D. Engel R. Kissling W. Davis J. (2009 a) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429–447.
53. Leucht S. Corves C. Arbter D. Engel R. Li C. Davis J. (2009 b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.
54. Leucht S. Heres S. (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67(Suppl. 5): 3–8.
55. Leucht S. Heres S. Hamann J. Kane J. (2008) Methodological issues in current antipsychotic drug trials. Schizophr Bull 34: 275–285.
56. Leucht S. Heres S. Kissling W. Davis J. (2011 b) Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14: 269–284.
57. Leucht S. Hierl S. Kissling W. Dold M. Davis J.M. (2012 a) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200: 97–106.
58. Leucht S. Kissling W. McGrath J. (2007) Lithium for schizophrenia. Cochrane Database Syst Rev 3: CD003834.
59. Leucht S. Komossa K. Rummel-Kluge C. Corves C. Hunger H. Schmid F. et al. (2009 c) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166: 152–163.
60. Leucht S. Tardy M. Komossa K. Heres S. Kissling W. Salanti G. et al. (2012 b) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379: 2063–2071.
61. Licht R. (2002) Limits of the applicability and generalizability of drug trials in mania. Bipolar Disord 4(Suppl. 1): 66–68.
62. Licht R. Nielsen J. Gram L. Vestergaard P. Bendz H. (2010) Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 12: 483–493.
63. Lieberman J. Stroup T. McEvoy J. Swartz M. Rosenheck R. Perkins D. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223.
64. Manschreck T. Boshes R. (2007) The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 15: 245–258.
65. March J. Silva S. Compton S. Shapiro M. Califf R. Krishnan R. (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162: 836–846.
66. McCombs J. Ganapathy V. Zolfaghari S. (2011) Applying comparative effectiveness research methods in bipolar disorders. J Affect Disord 130: 145–154.
67. McEvoy J. Lieberman J. Perkins D. Hamer R. Gu H. Lazarus A. et al. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1050–1060.
68. McKeage K. Plosker G. (2004) Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18: 933–956.
69. Meltzer H. Massey B. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11: 59–67.
70. Merikangas K. Jin R. He J. Kessler R. Lee S. Sampson N. et al. (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68: 241–251.
71. Miller G. (2010) Is pharma running out of brainy ideas? Science 329: 502–504.
72. Miyamoto S. Duncan G.E. Marx C.E. Lieberman J.A. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry, 10, 79–104.
73. Miyamoto S. Miyake N. Jarskog L. Fleischhacker W. Lieberman J. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 15 May (Epub ahead of print).
74. Naber D. Lambert M. (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23: 649–659.
75. Nasrallah H. (2007) The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 68(Suppl. 1): 5–11.
76. Newcomer J. (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl. 4): 8–13.
77. Nivoli A. Murru A. Goikolea J. Crespo J. Montes J. Gonzalez-Pinto A. et al. (2012) New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 140: 125–141.
78. Perala J. Suvisaari J. Saarni S. Kuoppasalmi K. Isometsa E. Pirkola S. et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64: 19–28.
79. Perlis R. Perlis C. Wu Y. Hwang C. Joseph M. Nierenberg A. (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162: 1957–1960.
80. Qian K. Di Lieto A. Corander J. Auvinen P. Greco D. (2012) Re-analysis of bipolar disorder and schizophrenia gene expression complements the Kraepelinian dichotomy. Adv Exp Med Biol 736: 563–577.
81. Rosa A. Reinares M. Michalak E. Bonnin C. Sole B. Franco C. et al. (2010) Functional impairment and disability across mood states in bipolar disorder. Value Health 13: 984–988.
82. Roth B.L. Sheffler D.J. Kroeze W.K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov, 3, 353–359.
83. Rummel-Kluge C. Komossa K. Schwarz S. Hunger H. Schmid F. Kissling W. et al. (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38: 167–177.
84. Rummel-Kluge C. Komossa K. Schwarz S. Hunger H. Schmid F. Lobos C. et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123: 225–233.
85. Schwarz C. Volz A. Li C. Leucht S. (2008) Valproate for schizophrenia. Cochrane Database Syst Rev 3: CD004028.
86. Shen W. (1999) A history of antipsychotic drug development. Compr Psychiatry 40: 407–414.
87. Smith L. Cornelius V. Warnock A. Tacchi M. Taylor D. (2007) Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 9: 551–560.
88. Smith M. Hopkins D. Peveler R. Holt R. Woodward M. Ismail K. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192: 406–411.
89. Stroup T. Alves W. Hamer R. Lieberman J. (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 5: 133–146.
90. Swainston Harrison T. Perry C. (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64: 1715–1736.
91. Tarr G. Glue P. Herbison P. (2011) Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania – a systematic review and meta-analysis. J Affect Disord 134: 14–19.
92. Tiihonen J. Haukka J. Taylor M. Haddad P. Patel M. Korhonen P. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–609.
93. Tiihonen J. Lonnqvist J. Wahlbeck K. Klaukka T. Niskanen L. Tanskanen A. et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620–627.
94. Ustun T. Rehm J. Chatterji S. Saxena S. Trotter R. Room R. et al. (1999) Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO / NIH Joint Project CAR Study Group. Lancet 354: 111–115.
95. Wahlbeck K. Cheine M. Essali M. (2000) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2: CD000059.
96. Williams M. (2011) Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther 336: 3–8.